Compounded Tirzepatide in 2026: What's Actually Changed and What to Fix Now
The tirzepatide shortage is over and the compliance gray area went with it. Here's what changed, what's still allowed, and how to audit your program.
If your GLP-1 weight loss program was built during the 2023-2024 shortage window, it was likely built on rules that no longer apply. The shortage that gave 503A and 503B pharmacies flexibility to compound tirzepatide ended over a year ago, and the enforcement posture has tightened considerably since. This is educational information, not legal advice — confirm specifics with your healthcare attorney and medical director before making changes to your program.
Why the Shortage Ending Changed Everything
Compounding flexibility for a brand-name drug like tirzepatide (the active ingredient in Mounjaro and Zepbound) exists specifically to cover a documented shortage. Once FDA declared that shortage resolved — October 2024, with enforcement discretion ending for 503A pharmacies in February 2025 and 503B facilities in March 2025 — that flexibility went away. Compounding a copy of an FDA-approved drug outside of a shortage is only lawful in narrow circumstances tied to genuine, documented clinical need for an individual patient. Cost or convenience isn't one of those circumstances.
As of an April 2026 proposal, the FDA has also moved to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely — which would close off large-scale outsourced compounding of these drugs altogether if finalized.
"Personalized" Isn't a Workaround
Some pharmacies have tried adding B12 or amino acids to a compounded GLP-1 and marketing it as a "personalized" formulation distinct from the branded product. FDA guidance doesn't treat that as a meaningful distinction — a documented, patient-specific clinical necessity is still the bar, not an additive. Research has also identified compounds formed when tirzepatide is combined with B12 that don't exist in the FDA-approved product, with unknown safety implications. That's not a detail worth building a program around.
Where Clinics Actually Get Exposed
Marketing language. FDA warning letters sent to telehealth operators specifically called out phrases like "same active ingredient as Mounjaro" or anything implying the compounded product carries FDA approval or clinical trial backing. Compounded drugs are, definitionally, not FDA-approved — marketing copy that blurs that line is one of the fastest ways to draw regulatory attention. Audit your website, ads, intake forms, and staff scripts for this language now.
Vendor documentation. The FDA has identified counterfeit compounded tirzepatide circulating with fabricated pharmacy information on the label. Every vendor needs a verified license, correct 503A/503B classification, current state permissions, and a certificate of analysis on every batch — not a one-time check at onboarding.
Documentation gaps. Every GLP-1 patient needs full history, contraindication screening (particularly for medullary thyroid carcinoma and MEN-2), and informed consent completed the same visit as the prescription — plus follow-up documentation at regular intervals. Inconsistent charting is one of the first things an inspector will find.
A Practical Audit Checklist
Vet every vendor against current licensing and documentation standards — pause ordering from anyone who can't confirm compliance.
Rewrite patient-facing language across the website, ads, and intake materials to remove anything implying FDA approval or brand equivalence.
Standardize the workflow — intake, screening, consult, prescribing, dispensing, follow-up, refill, discontinuation — so every patient gets the same documented process, not a variation by provider or location.
Train non-clinical staff on what they can and can't say to patients about compounded medications; clinical questions route to clinical staff, full stop.
Confirm your state layer. Federal rules are the floor, not the ceiling — several state boards have already disciplined telehealth-only GLP-1 prescribers independent of FDA action.
Where Multi-Location Programs Get This Right
The clinics handling this well aren't relying on individual providers to stay current on a fast-moving regulatory picture — they've centralized vendor vetting, standardized documentation templates, and put medical director review in front of any new sourcing decision. That's the practical value of a physician-led oversight structure here: consistency across every location, instead of every clinic independently interpreting the same shifting rules.
The Bottom Line
The compliance gray area that existed during the shortage is closed. Clinics running a defensible GLP-1 program in 2026 are the ones treating documentation, vendor vetting, and patient-facing language as the actual product — not an afterthought behind the medication itself.
Frequently Asked Questions
Is compounded tirzepatide still legal in 2026? It remains available only in narrow circumstances tied to documented, patient-specific clinical need. The shortage-era flexibility that allowed widespread compounding ended in 2024-2025, and the FDA is now proposing to remove these drugs from the 503B Bulks List.
What changed when the shortage ended? The FDA ended enforcement discretion for 503A pharmacies in February 2025 and 503B facilities in March 2025. Compounding a copy of an FDA-approved drug like tirzepatide is no longer broadly permitted.
Can a clinic market compounded tirzepatide as "the same as Mounjaro"? No. Compounded drugs are not FDA-approved, and language implying brand equivalence, FDA approval, or clinical trial backing is exactly the kind of claim that has drawn FDA warning letters.
What documentation should a GLP-1 program have for every patient? Full history, contraindication screening (especially for medullary thyroid carcinoma and MEN-2), informed consent completed the same visit as the prescription, and structured follow-up notes at regular intervals.
How can a multi-location clinic keep GLP-1 compliance consistent? Centralize vendor vetting, standardize documentation templates, and require medical director review before any new sourcing decision — so every location follows the same process instead of interpreting rules independently.
Not sure your current compounded tirzepatide program would hold up to a 2026 audit? Talk to Wellness MD Group about a compliance review before the next enforcement wave hits.